Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in September 2011 on request of the Sponsor.
On 5 December 2001, orphan designation (EU/3/01/073) was granted by the European Commission to NeuTec Pharma plc, United Kingdom, for recombinant human monoclonal antibody to hsp90 for the treatment of invasive fungal infections.
The sponsorship was transferred to Novartis Europharm Limited, in June 2007.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Recombinant human monoclonal antibody to hsp90
|Disease / condition||
Treatment of invasive fungal infections
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.